{"id":"NCT03675737","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)","officialTitle":"A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroesophageal Junction Adenocarcinoma (KEYNOTE-859)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-08","primaryCompletion":"2022-10-03","completion":"2025-03-03","firstPosted":"2018-09-18","resultsPosted":"2023-10-12","lastUpdate":"2025-07-24"},"enrollment":1579,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Stomach Neoplasms"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["KEYTRUDA®","MK-3475"]},{"type":"DRUG","name":"Cisplatin","otherNames":["PLATINOL®"]},{"type":"DRUG","name":"5-fluorouracil","otherNames":["ADRUCIL®","5FU"]},{"type":"DRUG","name":"oxaliplatin","otherNames":["ELOXATIN®"]},{"type":"DRUG","name":"capecitabine","otherNames":["XELODA®"]},{"type":"DRUG","name":"Placebo for Pembrolizumab","otherNames":[]}],"arms":[{"label":"Pembrolizumab + Chemotherapy (FP or CAPOX regimen)","type":"EXPERIMENTAL"},{"label":"Placebo + Chemotherapy (FP or CAPOX regimen)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil \\[FP regimen\\] or oxaliplatin combined with capecitabine \\[CAPOX regimen\\]) versus placebo in combination with chemotherapy (FP or CAPOX regimens) in the treatment of human epidermal growth factor receptor 2 (HER2) negative advanced gastric or GEJ adenocarcinoma in adult participants.\n\nThe primary hypotheses of this study are that pembrolizumab plus chemotherapy is superior to placebo plus chemotherapy in terms of overall survival (OS).","primaryOutcome":{"measure":"Overall Survival (OS) in All Participants","timeFrame":"Up to 45.9 months","effectByArm":[{"arm":"Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)","deltaMin":12.9,"sd":null},{"arm":"Placebo + Chemotherapy (FP or CAPOX Regimen)","deltaMin":11.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":29},"locations":{"siteCount":215,"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","Colombia","Costa Rica","Czechia","Denmark","France","Germany","Guatemala","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Mexico","New Zealand","Peru","Poland","Russia","South Africa","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["37875143","40025394","40750941","33975465"],"seeAlso":["https://www.merckclinicaltrials.com","https://msd.trialsummaries.com/Study/StudyDetails?id=26343&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":355,"n":785},"commonTop":["Nausea","Anaemia","Diarrhoea","Vomiting","Decreased appetite"]}}